Kristopher T Kahle Selected Research

Member 2 Solute Carrier Family 12

1/2022	NF-κB Signaling-Mediated Activation of WNK-SPAK-NKCC1 Cascade in Worsened Stroke Outcomes of Ang II-Hypertensive Mice.
8/2017	WNK-Cab39-NKCC1 signaling increases the susceptibility to ischemic brain damage in hypertensive rats.
6/2016	Gain-of-function missense variant in SLC12A2, encoding the bumetanide-sensitive NKCC1 cotransporter, identified in human schizophrenia.
1/2013	Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures.
9/2010	Progressive NKCC1-dependent neuronal chloride accumulation during neonatal seizures.
9/2010	Molecular mechanisms of microvascular failure in central nervous system injury--synergistic roles of NKCC1 and SUR1/TRPM4.
6/2010	Role of NKCC1 and KCC2 in the development of chronic neuropathic pain following spinal cord injury.
9/2008	The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kristopher T Kahle Research Topics

Disease

19	Hypertension (High Blood Pressure) 01/2022 - 01/2003
12	Hydrocephalus (Hydrocephaly) 04/2022 - 11/2016
11	Brain Edema (Cerebral Edema) 10/2020 - 09/2008
11	Seizures (Absence Seizure) 01/2019 - 09/2008
10	Epilepsy (Aura) 01/2021 - 12/2010
10	Neoplasms (Cancer) 01/2020 - 11/2011
10	Pseudohypoaldosteronism 12/2010 - 01/2003
10	Hyperkalemia 03/2009 - 01/2003
8	Stroke (Strokes) 04/2022 - 08/2009
7	Edema (Dropsy) 01/2017 - 09/2010
6	Ischemic Stroke 04/2022 - 01/2011
6	Scoliosis 07/2021 - 08/2019
6	Neuralgia (Stump Neuralgia) 03/2016 - 09/2008
5	Glioma (Gliomas) 01/2020 - 11/2011
5	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2015 - 09/2008
3	Brain Neoplasms (Brain Tumor) 04/2022 - 02/2014
3	Brain Injuries (Brain Injury) 04/2022 - 01/2014
3	Arnold-Chiari Malformation (Arnold-Chiari Syndrome) 01/2021 - 09/2011
3	Peripheral Nervous System Diseases (PNS Diseases) 01/2021 - 01/2016
3	Inflammation (Inflammations) 01/2020 - 02/2014
3	Aneurysm (Aneurysms) 01/2018 - 07/2011
3	Wounds and Injuries (Trauma) 01/2017 - 09/2010
3	Schizophrenia (Dementia Praecox) 06/2016 - 07/2014
3	Ischemia 07/2015 - 09/2010
2	Normal Pressure Hydrocephalus 04/2022 - 01/2021
2	Ataxia (Dyssynergia) 01/2021 - 01/2020
2	Anemia 01/2021 - 01/2021
2	Glioblastoma (Glioblastoma Multiforme) 01/2020 - 01/2012
2	Paralysis (Palsy) 01/2020 - 08/2019
2	Drug Resistant Epilepsy 01/2019 - 09/2011
2	Craniosynostoses (Craniosynostosis) 01/2018 - 01/2017
2	Hemorrhage 01/2017 - 06/2012
2	Essential Hypertension 01/2017 - 07/2014
2	Pain (Aches) 03/2016 - 06/2010
2	Autistic Disorder (Autism) 01/2015 - 07/2014
2	Autism Spectrum Disorder 01/2015 - 10/2012
2	Idiopathic Generalized Epilepsy 01/2015 - 07/2014
2	Hypoxia (Hypoxemia) 02/2014 - 01/2013
2	Temporal Lobe Epilepsy 01/2013 - 03/2008
2	Nervous System Diseases (Neurological Disorders) 10/2012 - 09/2008
2	Intracranial Aneurysm (Cerebral Aneurysm) 09/2011 - 07/2011
1	Bacteremia 06/2022
1	Abscess 06/2022
1	Osteomyelitis 06/2022
1	Traumatic Subarachnoid Hemorrhage 04/2022
1	Infections 04/2022
1	Body Weight (Weight, Body) 01/2022
1	Aarskog Syndrome 01/2022
1	Necrosis 01/2022
1	Medulloblastoma 01/2022

Drug/Important Bio-Agent (IBA)

17	Phosphotransferases (Kinase)IBA 04/2022 - 01/2003
11	K Cl- CotransportersIBA 01/2021 - 09/2008
10	Bumetanide (Bumex)FDA LinkGeneric 08/2017 - 09/2008
10	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2017 - 01/2003
10	ChloridesIBA 01/2017 - 09/2004
8	Member 2 Solute Carrier Family 12IBA 01/2022 - 09/2008
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2010
8	gamma-Aminobutyric Acid (GABA)IBA 10/2020 - 09/2008
7	Lysine (L-Lysine)FDA Link 01/2022 - 01/2003
5	Alanine (L-Alanine)FDA Link 04/2022 - 05/2014
5	Proline (L-Proline)FDA Link 04/2022 - 05/2014
5	SaltsIBA 06/2019 - 04/2008
5	CationsIBA 06/2016 - 02/2006
5	Anticonvulsants (Antiepileptic Drugs)IBA 06/2014 - 09/2008
4	Pharmaceutical PreparationsIBA 01/2020 - 01/2014
4	Ion Channels (Ion Channel)IBA 11/2016 - 08/2009
4	Aminobutyrates (Aminobutyric Acid)IBA 06/2016 - 05/2014
4	DiureticsIBA 04/2013 - 09/2008
3	Sodium-Potassium-Chloride SymportersIBA 04/2022 - 07/2015
3	ElectrolytesIBA 01/2021 - 08/2019
3	Furosemide (Lasix)FDA LinkGeneric 11/2016 - 09/2008
2	Protein Isoforms (Isoforms)IBA 01/2022 - 01/2012
2	Angiotensin IIIBA 01/2022 - 03/2009
2	Protein Kinases (Protein Kinase)IBA 01/2021 - 10/2010
2	Neural Cell Adhesion Molecule L1 (L1 Cell Adhesion Molecule)IBA 01/2019 - 01/2019
2	Acetazolamide (Diamox)FDA LinkGeneric 11/2016 - 02/2011
2	Small Interfering RNA (siRNA)IBA 07/2015 - 02/2014
2	Immunoglobulin E (IgE)IBA 01/2015 - 07/2014
2	Analgesics (Analgesic Drugs)IBA 07/2014 - 06/2010
2	Temozolomide (Temodar)FDA LinkGeneric 02/2014 - 01/2012
2	Phenobarbital (Luminal)FDA Link 01/2013 - 09/2010
2	SteroidsIBA 05/2012 - 03/2007
2	Adenosine Triphosphate (ATP)IBA 01/2012 - 09/2010
2	SymportersIBA 01/2012 - 03/2006
1	Methicillin (Metin)FDA Link 06/2022
1	salicylhydroxamic acid (SHAM)IBA 04/2022
1	Bevacizumab (Avastin)FDA Link 01/2022
1	Trans-Activators (Trans-Acting Factor)IBA 01/2022
1	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 01/2022
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022

Therapy/Procedure

22	Therapeutics 01/2022 - 06/2010
6	Craniotomy 04/2022 - 01/2011
6	Spinal Fusion (Spondylosyndesis) 07/2021 - 08/2019
5	Length of Stay 01/2021 - 08/2019
5	Radiotherapy 01/2020 - 10/2011
4	Decompression 01/2021 - 09/2011
3	Decompressive Craniectomy 02/2016 - 01/2013
2	Patient Discharge 10/2011 - 01/2011
1	Cerebrospinal Fluid Shunts 04/2022
1	Hyperbaric Oxygenation 01/2022